The prospective study of blood biomarker and gut microbiota in the patients treated with anti-PD 1 antibody for advanced non-small cell lung cancer

The prospective study of blood biomarker and gut microbiota in the patients treated with anti-PD 1 antibody for advanced non-small cell lung cancer - Biomarker study for nivolumab

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000021734

Enrollment

Registered

2016-05-01

Start date

2016-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criterion of the present study is the patients who treated with chemotherapy at Komagome Hospital. Before being underwent chemotherapy, the patients examined blood sample with tube (or EDTA) contains sodium heparin of up to 14mL and/or fece.

Exclusion criteria

Exclusion criteria: Other than that above

Design outcomes

Primary

Measure	Time frame
To investigate correlation between soluble PD-L1 or other biomarkers and clinical response or toxicities	—

Countries

Japan

Contacts

Public ContactYusuke Okuma

Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital Department of Thoracic Oncology and Respiratory Medicine

y-okuma@cick.jp03-3823-2101

Outcome results